Cell No. 1 Interpretation of a cancer cell, provided by Angela Canada Hopkins, daughter of a cancer patient.

Committed to advancing new medicines to benefit patients with viral-associated cancers and other serious diseases.

Cell No. 1 Interpretation of a cancer cell, provided by Angela Canada Hopkins, daughter of a cancer patient.

Who We Are

Viracta Therapeutics is a clinical-stage drug development company focused on advancing a proprietary viral activation therapy platform to address cancers associated with the Epstein-Barr Virus (EBV) and additional virus-associated diseases.

Who We Are

Viracta Therapeutics is a clinical-stage drug development company focused on advancing a proprietary viral activation therapy platform to address cancers associated with the Epstein-Barr Virus (EBV) and additional virus-associated diseases.

Recent News

April 4, 2017

NantKwest and Viracta Therapeutics Announce Series B Financing and Immunotherapy Partnership - Culver City and San Diego, April 4, 2017 - NantKwest, Inc. (Nasdaq:NK) and Viracta Therapeutics, Inc. announced the initial closing of a Series B Preferred financing round of up to $18.4 million with NantKwest, Inc. [NASDAQ:NK] as the lead investor. Read More

January 9, 2017

BioCentury - Viral Vulnerability - Persistent viral infection, even those that are undetectable or asymptomatic, can cause some cancers and contribute to their severity. Viracta Therapeutics Inc. is treating virus-associated cancers by forcing them to re-express latent viral proteins that make cancerous cells vulnerable to antiviral treatment. Read More

Events

April 20, 2017

Ivor Royston will speak at The 8th China-US Business Leaders Conference in New York City Agenda | Ascentage Forum

April 7, 2017

Viracta selected to present at BioCentury’s Future Leaders in the Biotech Industry Conference Read More

January 9, 2017

Viracta will present at the 9th Annual Biotech Showcase Conference in San Francisco Read More

Recent News

April 4, 2017

NantKwest and Viracta Therapeutics Announce Series B Financing and Immunotherapy Partnership - Culver City and San Diego, April 4, 2017 - NantKwest, Inc. (Nasdaq:NK) and Viracta Therapeutics, Inc. announced the initial closing of a Series B Preferred financing round of up to $18.4 million with NantKwest, Inc. [NASDAQ:NK] as the lead investor. Read More

January 9, 2017

BioCentury - Viral Vulnerability - Persistent viral infection, even those that are undetectable or asymptomatic, can cause some cancers and contribute to their severity. Viracta Therapeutics Inc. is treating virus-associated cancers by forcing them to re-express latent viral proteins that make cancerous cells vulnerable to antiviral treatment. Read More

Events

April 20, 2017

Ivor Royston will speak at The 8th China-US Business Leaders Conference in New York City Agenda | Ascentage Forum

April 7, 2017

Viracta selected to present at BioCentury’s Future Leaders in the Biotech Industry Conference Read More

January 9, 2017

Viracta will present at the 9th Annual Biotech Showcase Conference in San Francisco Read More